ALPMY News and Press, Astellas Pharma Inc. ADR From 06/08/23

Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 PR Newswire KT430 is a preclinical, next-generation investigational gene therapy to treat X-linked myotubular myopathy (XLMTM) TOKYO and SAN DIEGO , June 8, 2023 /PRNewswire...

2023-05-30 15:02:46 ET Summary Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc. Iveric bio, Inc. stock trades at a discount of over 5% for an acquisition that is targeted to close in the third calendar q...

Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting PR Newswire Data at meeting illustrate company's progress in addressing unmet needs in a broad range of hard-to-treat solid tumors and hematologic malignancies ...

2023-05-25 07:42:54 ET Summary Patients with upper GI cancers are in dire need of new therapeutic options. Astellas is sitting on a shoo-in approval for a brand new targeted therapy based on highly promising clinical trial data. An approval in this space could mean important n...

Astellas Announces Commitments to 3rd Phase of GHIT Fund Replenishment PR Newswire TOKYO , May 25, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has committed to supporti...

2023-05-18 08:20:30 ET FibroGen's ( NASDAQ: FGEN ) oral drug roxadustat was good as recombinant erythropoietin alfa (SEPO) in improving hemoglobin (Hb) level in a phase 3 trial to treat anemia in patients receiving chemotherapy for non-myeloid malignancies in China. Anemia ...

Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field PR Newswire - Conduct collaborative research on Sony's unique polymeric materials to achieve high- DAR ADC - TOKYO , May 16, 2023 /PR...

2023-05-12 14:42:30 ET The US FDA has granted approval to Astellas Pharma's ( OTCPK:ALPMF )( OTCPK:ALPMY ) Veozah (fezolinetant) for hot flashes associated with menopause. The agency noted that the drug is the first neurokinin 3 (NK3) receptor antagonist approved for the condi...

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause PR Newswire VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause TOKYO , May 1...

2023-05-09 08:56:49 ET Leading drugmakers are prepping for a legal fight against recently implemented U.S. drug pricing reforms which bring negotiating power to Medicare for the first time ever, Reuters reported Tuesday, citing industry sources. In March, the Centers for Medicare &a...